News | September 12, 2014

Mevion Medical Systems Introduces Hyperscan for Mevion S250 Platform

 Mevion_HYPERSCAN Proton Therapy
 Mevion_HYPERSCAN Proton Therapy

September 12, 2014 — Mevion Medical Systems introduced Hyperscan for the Mevion S250 modular single-room proton therapy system. Benefiting from direct and efficient proton beam generation, Hyperscan’s patented technology allows radiation to be precisely delivered using a sharp beam of radiation, with the tumor being volumetrically scanned in a matter of seconds. Current pencil beam delivery systems are known to be sensitive to motion, which can result in higher treatment uncertainties. Hyperscan’s fast beam delivery is much less sensitive to patient and tumor motions, thus delivering a more robust treatment.

“Hyperscan enables treatment with fine precision at tremendous speed and with uncompromised beam quality,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems. “This new technological advance will help providers deliver the best possible cancer care to the patients who need it most.”

Hyperscan is debuting at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), being held Sept. 14-16 in San Francisco. It is built on the Mevion S250 proton therapy platform that has been operating clinically since December 2013. The Hyperscan system features rapid volumetric and layer rescanning, a streamlined image-based clinical workflow, sub-millimeter position tracking and beam gating connectivity.

Simultaneously, Mevion is announcing it has reached an agreement with a financial services provider to offer financing to customers interested in purchasing the Mevion S250. This will provide Mevion’s customers with an alternative to traditional financing structures, should they desire it.

“The introduction of Hyperscan technology and the availability of alternative financing is a demonstration of Mevion’s continued commitment to improving the worldwide availability and clinical use of proton therapy,” said Jachinowski. “Mevion is dedicated to removing the obstacles of size, complexity and cost that exist with conventional proton therapy systems and making proton therapy as accessible as possible to the cancer patients who need it.”

The U.S. Food and Drug Administration (FDA) has not cleared Hyperscan for clinical use.

For more information:

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
Netherlands Proton Therapy Center Delivers First Clinical Flash Irradiation
News | Proton Therapy | May 02, 2019
IBA (Ion Beam Applications SA) recently announced the first Flash irradiation in an IBA proton therapy gantry treatment...
Pencil Beam Scanning Better Protects Children With Brain Tumors
News | Proton Therapy | May 01, 2019
A comparison of three types of radiotherapy for children's brain tumors suggests a type of proton therapy called pencil...
California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment
News | Proton Therapy | April 25, 2019
California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast...
Varian Discloses First Preclinical Results of Flash Therapy in Cancer Treatment
News | Proton Therapy | April 09, 2019
Varian, in partnership with the University of Maryland School of Medicine’s Department of Radiation Oncology and the...
ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
What to Expect from the Proton Therapy Market in 2019-2020
News | Proton Therapy | March 13, 2019
The number of new particle therapy rooms ordered worldwide dropped by almost 20 percent in 2018, according to a new...
Videos | Proton Therapy | March 01, 2019
ITN Associate Editor Jeff Zagoudis speaks with Mark Pankuch, Ph.D., director of physics and dosimetry at the...
Videos | Proton Therapy | February 28, 2019
ITN Associate Editor Jeff Zagoudis speaks with ...